Dilated Cardiomyopathy Therapeutic Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Dilated Cardiomyopathy Therapeutics Market is Segmented by Drug Class (Aldosterone antagonists, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers, Beta-blockers), and Geography

Market Snapshot

dilated-cardiomyopathy-therapeutic-market_Market Summary
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 3.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The dilated cardiomyopathy therapeutics market is anticipated to grow with a CAGR of nearly 3.6% during the forecast period. The major factors attributing to the growth of the dilated cardiomyopathy therapeutics market are increasing life expectancy and increasing prevalence of heart problems. Furthermore, the increasing number of people suffering from cardiac muscle infections, along with the drug or alcohol abuse are also the major factors that help in driving the growth of the market.

As the incidence of cardiovascular diseases is increasing which is directly proportional to the market growth. Whereas the side effects of dilated cardiomyopathy therapeutics that cause serious discomfort to the patients are restraining the market.

Scope of the Report

According to the scope of the report dilated cardiomyopathy is a disease of the heart muscle, usually starting in the heart's main pumping chamber (left ventricle). The ventricle stretches and thins (dilates) and can't pump blood as well as a healthy heart can. In a general term, it refers to the abnormality of the heart muscle itself.

By Drug Class
Aldosterone antagonists
Angiotensin-converting enzyme (ACE) Inhibitors
Angiotensin II Receptor Blockers
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Angiotensin II receptor blockers is Expected to Dominate the Growth of the Market

Angiotensin II receptor blockers acquire the largest market share followed by beta-blockers. This is attributed to the high demand for blockbuster drugs in dilated cardiomyopathy treatment, especially in developed regions. Aldosterone antagonists recorded a high growth rate due to the identified positive impact of aldosterone antagonists when used in combination with either ARBs or ACE inhibitors in reducing the progression of Duchenne muscular dystrophy (DMD). Approval for this indication would further accelerate the overall sales of aldosterone antagonists, which in turn would positively impact market growth.

The other driving factors of the segment are also related to the increasing prevalence of heart diseases. Therefore as the prevalence of heart diseases increases the growth of the market increases too.

Heart diseases.png

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall dilated cardiomyopathy therapeutics market, throughout the forecast period. The growth is due to the rising incidence of cardiovascular diseases, well-established insurance policies and the availability of advanced healthcare infrastructure are the major factors. 

In the North America region, the United States holds the largest market share due to factors such as an increasing number of geriatric populations, along with a growing number of heart diseases in the country, which is anticipated to stimulate the demand in this region. Therefore as the number of cardiovascular diseases increases the market for dilated cardiomyopathy also increases.

Dilated Cardiomyopathy Therapeutic Market

Competitive Landscape

The dilated cardiomyopathy therapeutics market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc, AstraZeneca plc., Vericel Corporation, Pfizer inc., t2cure GmbH, MyoKardia, and Kasiak Research pvt.ltd.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Heart Diseases

      2. 4.2.2 Increasing Drugs and Alcohol Abuse

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects of Dilated Cardiomyopathy Therapeutics

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Class

      1. 5.1.1 Aldosterone antagonists

      2. 5.1.2 Angiotensin-converting enzyme (ACE) Inhibitors

      3. 5.1.3 Angiotensin II Receptor Blockers

      4. 5.1.4 Beta-blockers

    2. 5.2 Geography

      1. 5.2.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.2.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.2.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Zensun Shanghai Sci & Tech Co Ltd

      2. 6.1.2 Capricor Therapeutics, Inc.

      3. 6.1.3 Vericel Corporation

      4. 6.1.4 AstraZeneca plc.

      5. 6.1.5 Pfizer Inc.

      6. 6.1.6 t2cure GmbH

      7. 6.1.7 MyoKardia and Kasiak Research pvt.ltd.

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Dilated Cardiomyopathy Therapeutic Market market is studied from 2018 - 2026.

The Dilated Cardiomyopathy Therapeutic Market is growing at a CAGR of 3.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc., Vericel Corporation, AstraZeneca plc., Pfizer Inc. are the major companies operating in Dilated Cardiomyopathy Therapeutic Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!